{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"16.3"},{"groupId":"OG001","value":"14.7"},{"groupId":"OG002","value":"18.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"136"},{"groupId":"OG001","value":"70"},{"groupId":"OG002","value":"66"}],"units":"Participants"},{"counts":[{"groupId":"OG000","value":"282"},{"groupId":"OG001","value":"143"},{"groupId":"OG002","value":"139"}],"units":"Responses"}],"title":"SC Preference: Feels Less Emotionally Distressing"},{"categories":[{"measurements":[{"groupId":"OG000","value":"42.2"},{"groupId":"OG001","value":"42.0"},{"groupId":"OG002","value":"42.4"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"136"},{"groupId":"OG001","value":"70"},{"groupId":"OG002","value":"66"}],"units":"Participants"},{"counts":[{"groupId":"OG000","value":"282"},{"groupId":"OG001","value":"143"},{"groupId":"OG002","value":"139"}],"units":"Responses"}],"title":"SC Preference: Requires Less Time in the Clinic"},{"categories":[{"measurements":[{"groupId":"OG000","value":"11.3"},{"groupId":"OG001","value":"9.8"},{"groupId":"OG002","value":"12.9"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"136"},{"groupId":"OG001","value":"70"},{"groupId":"OG002","value":"66"}],"units":"Participants"},{"counts":[{"groupId":"OG000","value":"282"},{"groupId":"OG001","value":"143"},{"groupId":"OG002","value":"139"}],"units":"Responses"}],"title":"SC Preference: Lower Level of Injection-Site Pain"},{"categories":[{"measurements":[{"groupId":"OG000","value":"25.9"},{"groupId":"OG001","value":"28.7"},{"groupId":"OG002","value":"23.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"136"},{"groupId":"OG001","value":"70"},{"groupId":"OG002","value":"66"}],"units":"Participants"},{"counts":[{"groupId":"OG000","value":"282"},{"groupId":"OG001","value":"143"},{"groupId":"OG002","value":"139"}],"units":"Responses"}],"title":"SC Preference: Feels More Comfortable During Administration"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.3"},{"groupId":"OG001","value":"4.9"},{"groupId":"OG002","value":"3.6"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"136"},{"groupId":"OG001","value":"70"},{"groupId":"OG002","value":"66"}],"units":"Participants"},{"counts":[{"groupId":"OG000","value":"282"},{"groupId":"OG001","value":"143"},{"groupId":"OG002","value":"139"}],"units":"Responses"}],"title":"SC Preference: Other Reason"},{"categories":[{"measurements":[{"groupId":"OG000","value":"16.7"},{"groupId":"OG001","value":"17.6"},{"groupId":"OG002","value":"16.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"12"}],"units":"Participants"},{"counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"25"}],"units":"Responses"}],"title":"IV Preference: Feels Less Emotionally Distressing"},{"categories":[{"measurements":[{"groupId":"OG000","value":"4.8"},{"groupId":"OG001","value":"5.9"},{"groupId":"OG002","value":"4.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"12"}],"units":"Participants"},{"counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"25"}],"units":"Responses"}],"title":"IV Preference: Requires Less Time in the Clinic"},{"categories":[{"measurements":[{"groupId":"OG000","value":"26.2"},{"groupId":"OG001","value":"23.5"},{"groupId":"OG002","value":"28.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"12"}],"units":"Participants"},{"counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"25"}],"units":"Responses"}],"title":"IV Preference: Lower Level of Injection-Site Pain"},{"categories":[{"measurements":[{"groupId":"OG000","value":"33.3"},{"groupId":"OG001","value":"47.1"},{"groupId":"OG002","value":"24.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"12"}],"units":"Participants"},{"counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"25"}],"units":"Responses"}],"title":"IV Preference: Feels More Comfortable During Administration"},{"categories":[{"measurements":[{"groupId":"OG000","value":"19.0"},{"groupId":"OG001","value":"5.9"},{"groupId":"OG002","value":"28.0"}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"22"},{"groupId":"OG001","value":"10"},{"groupId":"OG002","value":"12"}],"units":"Participants"},{"counts":[{"groupId":"OG000","value":"42"},{"groupId":"OG001","value":"17"},{"groupId":"OG002","value":"25"}],"units":"Responses"}],"title":"IV Preference: Other Reason"}],"denomUnitsSelected":"Responses","denoms":[{"counts":[{"groupId":"OG000","value":"158"},{"groupId":"OG001","value":"80"},{"groupId":"OG002","value":"78"}],"units":"Participants"},{"counts":[{"groupId":"OG000","value":"324"},{"groupId":"OG001","value":"160"},{"groupId":"OG002","value":"164"}],"units":"Responses"}],"description":"In Question 3 of the PPQ, participants who reported a preference for one of the two administration routes in Question 1 of the PPQ were asked to provide the two main reasons for their preference. The five available options for a participant's response were: Feels less emotionally distressing; Requires less time in the clinic; Lower level of injection-site pain; Feels more comfortable during administration; and Other reason.","groups":[{"description":"In the Treatment Cross-Over Period of the study, all participants received their first 6 cycles of treatment in accordance with the study arm to which they were randomized: Arm A) pertuzumab IV and trastuzumab IV (P+H IV) for 3 treatment cycles followed by the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles (1 cycle = 21 days); or Arm B) PH FDC SC for 3 treatment cycles followed by P+H IV for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized.","id":"OG000","title":"All Participants"},{"description":"In the Treatment Cross-Over Period of the study, participants randomized to Arm A first received pertuzumab IV and trastuzumab IV (P+H IV) administration for 3 treatment cycles followed by the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized.","id":"OG001","title":"A: P+H IV Followed by PH FDC SC"},{"description":"In the Treatment Cross-Over Period of the study, participants randomized to Arm B first received the pertuzumab and trastuzumab fixed-dose combination for subcutaneous administration (PH FDC SC) for 3 treatment cycles followed by pertuzumab intravenous (IV) and trastuzumab IV (P+H IV) administration for 3 treatment cycles (1 cycle = 21 days). Following completion of this study period, participants chose one of the two study treatments to receive in the Treatment Continuation Period for the remaining anti-HER2 treatment cycles (18 planned cycles in total, including pre-study neoadjuvant treatment). After completing study treatment, participants entered the Follow-up Period wherein they were to be followed for 3 years from the date the last participant was randomized.","id":"OG002","title":"B: PH FDC SC Followed by P+H IV"}],"paramType":"NUMBER","populationDescription":"Modified ITT (mITT) Population; for Question 3, the number analyzed for the two main reasons for SC or IV preference represents the participants who indicated in their responses to Question 1 of the PPQ that they preferred the SC or IV route of administration, respectively.","reportingStatus":"POSTED","timeFrame":"Cycle 6 Day 1 (each cycle is 21 days)","title":"Percentage of Responses From Participants to the Two Main Reasons for Their Preferred Method of Pertuzumab and Trastuzumab Administration, as Assessed in Question 3 of the Patient Preference Questionnaire (PPQ)","type":"SECONDARY","typeUnitsAnalyzed":"Responses","unitOfMeasure":"Percentage of responses"}